Title :

Liver transplantation for NAFLD cirrhosis: age and recent coronary angioplasty are major determinants of survival.

Author(s) :

Villeret, François [Auteur]
Hôpital de la Croix-Rousse [CHU - HCL]
Dharancy, Sebastien [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Poinsot-Erard, Domitille [Auteur]
Hospices Civils de Lyon [HCL]
Abergel, Armand [Auteur]
CHU Estaing [Clermont-Ferrand]
Barbier, Louise [Auteur]
Hôpital Trousseau
Besch, Camille [Auteur]
Hôpital de Hautepierre [Strasbourg]
Boillot, Olivier [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Boudjema, Karim [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Coilly, Audrey [Auteur]
Physiopathologie et traitement des maladies du foie
Conti, Filomena [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Corpechot, Christophe [Auteur]
CHU Saint-Antoine [AP-HP]
Duvoux, Christophe [Auteur]
Hôpital Henri Mondor
Faitot, François [Auteur]
Hôpital de Hautepierre [Strasbourg]
Faure, Stéphanie [Auteur]
Hôpital Saint Eloi [CHU Montpellier]
Francoz, Claire [Auteur]
Hôpital Beaujon [AP-HP]
Giostra, E. [Auteur]
Hardwigsen, Jean [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Hilleret, Marie-Noëlle [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Hiriart, Jean-Baptiste [Auteur]
Hôpital Haut-Lévêque [CHU Bordeaux]
Houssel-Debry, Pauline [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Kamar, Nassim [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Lassailly, Guillaume [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Latournerie, Marianne [Auteur]
Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand [CHU Dijon]
Pageaux, Georges-Philippe [Auteur]
Hôpital Saint Eloi [CHU Montpellier]
Samuel, Didier [Auteur]
Physiopathologie et traitement des maladies du foie
Vanlemmens, Claire [Auteur]
Hôpital JeanMinjoz
Saliba, Faouzi [Auteur]
Physiopathologie et traitement des maladies du foie
Dumortier, Jerôme [Auteur]
Université Claude Bernard Lyon 1 [UCBL]

Journal title :

Liver International

Abbreviated title :

Liver Int

Volume number :

42

Pages :

2428-2441

Publication date :

2022-08-05

ISSN :

1478-3231

English keyword(s) :

liver transplantation
metabolic syndrome
NAFLD
survival

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background and Aims Liver transplantation (LT) is the treatment of end-stage non-alcoholic liver disease (NAFLD), that is decompensated cirrhosis and/or complicated by hepatocellular carcinoma (HCC). Few data on long-term ...
Show more >Background and Aims Liver transplantation (LT) is the treatment of end-stage non-alcoholic liver disease (NAFLD), that is decompensated cirrhosis and/or complicated by hepatocellular carcinoma (HCC). Few data on long-term outcome are available. The aim of this study was to evaluate overall patient and graft survivals and associated predictive factors. Method This retrospective multicentre study included adult transplant patients for NAFLD cirrhosis between 2000 and 2019 in participating French-speaking centres. Results A total of 361 patients (69.8% of male) were included in 20 centres. The median age at LT was 62.3 years [57.4–65.9] and the median MELD score was 13.9 [9.1–21.3]; 51.8% of patients had HCC on liver explant. Between 2004 and 2018, the number of LT for NAFLD cirrhosis increased by 720%. A quarter of the patients had cardiovascular history before LT. Median follow-up after LT was 39.1 months [15.8–72.3]. Patient survival at 1, 5 and 10 years after LT was 89.3%, 79.8% and 68.1% respectively. The main causes of death were sepsis (37.5%), malignancies (29.2%) and cardiovascular events (22.2%). In multivariate analysis, three risk factors for overall mortality after LT were recipient pre-LT BMI < 32 kg/m2 at LT time (OR: 2.272; p = .012), pre-LT angioplasty during CV check-up (OR: 2.916; p = .016), a combined donor and recipient age over 135 years (OR: 2.020; 95%CI: p = .035). Conclusion Survival after LT for NAFLD cirrhosis is good at 5 years. Donor and recipient age, and cardiovascular history, are major prognostic factors to consider.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-12T00:54:28Z
2024-03-28T07:45:52Z